The expression levels of (a) GAS5, (b) linc0597, (c) lnc-DC, (d) lnc0640, (e) lnc5150, (f) lnc7074, (g) lncagf.1, (h) lnc3643, (i) lnc7514 and (j) lnc6655 between systemic lupus erythematosus (SLE) no lupus nephritis (LN) patients and LN patients in the training set.
Figure S3
The expression levels of (a) linc0597, (b) lnc-DC, (c) GAS5, (d) lnc0640, (e) lnc3643, (f) lnc5150, (g) lnc6655, (h) lnc7074 and (i) lnc7514 between systemic lupus erythematosus (SLE) patients and health controls in the combined set.
Figure S4
The expression levels of (a) linc0597, (b) lnc-DC, (c) GAS5, (d) lnc0640, (e) lnc3643, (f) lnc5150, (g) lnc6655, (h) lnc7074 and (i) lnc7514 between systemic lupus erythematosus (SLE) no lupus nephritis (LN) patients and LN patients in the combined set. 
